Publications
Detailed Information
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Cha, Yongjun | - |
dc.contributor.author | Choi, In-Sil | - |
dc.contributor.author | Yoon, So-Young | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Kim, Chang Duck | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.contributor.author | Kim, Jae Sun | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.contributor.author | Choi, In Keun | - |
dc.date.accessioned | 2012-05-29T08:56:43Z | - |
dc.date.available | 2012-05-29T08:56:43Z | - |
dc.date.issued | 2010-02 | - |
dc.identifier.citation | CANCER CHEMOTHERAPY AND PHARMACOLOGY; Vol.65 3; 527-536 | ko_KR |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76577 | - |
dc.description.abstract | To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer. Patients with locally advanced or metastatic or recurrent pancreatic adenocarcinoma, which was histologically or cytologically proven, with at least one measurable lesion were eligible for the study. Gemcitabine at a dose of 1,000 mg/m(2) was intravenously given over 30 min on days 1 and 8, while S-1 at a dose of 40 mg/m(2) was orally given twice daily from day 1 to 14, and the cycle was repeated every 3 weeks. The objective response rate, which was assessed according to RECIST criteria, was the primary end point. A total of 38 patients were enrolled between June 2006 and June 2007. The median number of treatment courses was 5.5 (range 1-22). Thirty-four patients were evaluable for response. Although no complete response was seen, partial responses were achieved in 11 patients, resulting in an overall response rate of 32% [95% confidence interval (CI) 17-48%]. The median response duration was 6.0 months (95% CI 4.6-8.3 months), the median time-to-progression was 5.4 months (95% CI 2.9-8.0 months), and the median overall survival was 8.4 months (95% CI 5.7-11.1 months). The major grade 3/4 hematologic toxicities were neutropenia (39.5%), leukopenia (15.8%), thrombocytopenia (2.6%), and anemia (7.9%). The major grade 3/4 non-hematologic toxicities included anorexia (10.5%), stomatitis (2.6%), rash (7.9%), fatigue (7.9%) and hyperbilirubinemia (5.3%). Gemcitabine and S-1 combination chemotherapy was effective and tolerable in patients with unresectable pancreatic cancer. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | SPRINGER | ko_KR |
dc.subject | Gemcitabine | ko_KR |
dc.subject | S-1 | ko_KR |
dc.subject | Palliative | ko_KR |
dc.subject | Pancreatic cancer | ko_KR |
dc.title | A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 오도윤 | - |
dc.contributor.AlternativeAuthor | 차용준 | - |
dc.contributor.AlternativeAuthor | 최인실 | - |
dc.contributor.AlternativeAuthor | 윤소영 | - |
dc.contributor.AlternativeAuthor | 최인근 | - |
dc.contributor.AlternativeAuthor | 김지현 | - |
dc.contributor.AlternativeAuthor | 오상철 | - |
dc.contributor.AlternativeAuthor | 김창덕 | - |
dc.contributor.AlternativeAuthor | 김재선 | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.contributor.AlternativeAuthor | 김열홍 | - |
dc.identifier.doi | 10.1007/s00280-009-1059-9 | - |
dc.citation.journaltitle | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.description.citedreference | Murakami Y, 2009, J GASTROINTEST SURG, V13, P85, DOI 10.1007/s11605-008-0650-4 | - |
dc.description.citedreference | Kim MK, 2009, JPN J CLIN ONCOL, V39, P49, DOI 10.1093/jjco/hyn126 | - |
dc.description.citedreference | LEE GW, 2009, CANC CHEMOT IN PRESS | - |
dc.description.citedreference | Wong D, 2008, PANCREAS, V37, P269 | - |
dc.description.citedreference | Bernhard J, 2008, J CLIN ONCOL, V26, P3695, DOI 10.1200/JCO.2007.15.6240 | - |
dc.description.citedreference | Murakami Y, 2008, AM J SURG, V195, P757, DOI 10.1016/j.amjsurg.2007.04.018 | - |
dc.description.citedreference | Okusaka T, 2008, CANCER CHEMOTH PHARM, V61, P615, DOI 10.1007/s00280-007-0514-8 | - |
dc.description.citedreference | Miksad RA, 2007, J CLIN ONCOL, V25, P4506, DOI 10.1200/JCO.2007.13.0401 | - |
dc.description.citedreference | Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886 | - |
dc.description.citedreference | Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525 | - |
dc.description.citedreference | UENO H, 2007, J CLIN ONCOL 1, V25 | - |
dc.description.citedreference | Heinemann V, 2006, J CLIN ONCOL, V24, P3946, DOI 10.1200/JCO.2005.05.1490 | - |
dc.description.citedreference | Nakamura K, 2006, BRIT J CANCER, V94, P1575, DOI 10.1038/sj.bjc.6603168 | - |
dc.description.citedreference | Oettle H, 2005, ANN ONCOL, V16, P1639, DOI 10.1093/annonc/mdi309 | - |
dc.description.citedreference | Nakamura K, 2005, BRIT J CANCER, V92, P2134, DOI 10.1038/sj.bjc.6602644 | - |
dc.description.citedreference | Louvet C, 2005, J CLIN ONCOL, V23, P3509 | - |
dc.description.citedreference | Ueno H, 2005, ONCOLOGY-BASEL, V68, P171, DOI 10.1159/000086771 | - |
dc.description.citedreference | SHIN HR, 2005, CANC RES TREAT, V37, P325 | - |
dc.description.citedreference | Ueno H, 2005, ONCOLOGY-BASEL, V69, P421, DOI 10.1159/000089997 | - |
dc.description.citedreference | CUNNINGHAM D, 2005, EUR J CANC, V4 | - |
dc.description.citedreference | Halloran CM, 2004, J GENE MED, V6, P514, DOI 10.1002/jgm.540 | - |
dc.description.citedreference | ROCHALIMA CM, 2004, J CLIN ONCOL, V22, P3776 | - |
dc.description.citedreference | Berlin JD, 2002, J CLIN ONCOL, V20, P3270, DOI 10.1200/JCO.2002.11.149 | - |
dc.description.citedreference | Bramhall SR, 2002, BRIT J CANCER, V87, P161, DOI 10.1038/sj.bjc.6600446 | - |
dc.description.citedreference | Colucci G, 2002, CANCER, V94, P902 | - |
dc.description.citedreference | Burris HA, 1997, J CLIN ONCOL, V15, P2403 | - |
dc.description.citedreference | Takechi T, 1997, CANCER CHEMOTH PHARM, V39, P205 | - |
dc.description.citedreference | Shirasaka T, 1996, ANTI-CANCER DRUG, V7, P548 | - |
dc.description.citedreference | LONGO DL, 1991, J CLIN ONCOL, V9, P2042 | - |
dc.description.tc | 8 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.